Evidence map›Paper›PMID 26878386›Full record

ArticleOncogenesis2016

A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls.

Y Wu, Y-Q Wang, W-W Weng, Q-Y Zhang, X-Q Yang, H-L Gan, Y-S Yang, P-P Zhang, M-H Sun, M-D Xu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Review
  11. Long noncoding RNATranslational andrology and urology · 2024
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. lncRNA PVT1: a novel oncogene in multiple cancers.Cellular & molecular biology letters · 2022
    Review
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Y WuDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
Y-Q WangDepartment of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
W-W WengDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
Q-Y ZhangDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
X-Q YangDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
H-L GanDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
Y-S YangDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
P-P ZhangDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
M-H SunDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
M-D XuDepartment of Pathology, Fudan University Shanghai Cancer center, Shanghai, China.
C-F WangDepartment of Pathology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serum biomarkers have not been fully incorporated into clinical use for the diagnosis of renal cell carcinoma (RCC). The recent discovery of long noncoding RNAs (lncRNAs), which have been reported in a variety of cancer types, suggested a promising new class of biomarkers for tumour diagnosis. The aim of our study was to evaluate whether the levels of circulating lncRNAs could be used as a tumour marker to discriminate between clear cell RCC (ccRCC) patients and healthy controls. Serum samples were collected from 71 ccRCC patients including 62 age- and sex-matched healthy controls and 8 patients with benign renal tumours. Eighty-two cancer-associated lncRNAs were assessed by reverse transcription and quantitative polymerase chain reaction in paired tissues and serum. A 5-lncRNA signature, including lncRNA-LET, PVT1, PANDAR, PTENP1 and linc00963, were identified and validated in the training set and testing set, respectively. The receiver operating characteristic curves for this serum 5-lncRNA signature were 0.900 and 0.823 for the two sets of serum samples. Moreover, five-minus-one lncRNA signatures demonstrated that none of the lncRNAs had a higher area under the curve than the others in either set. A risk model for the serum 5-lncRNA signature also determined that benign renal tumours can be distinguished from ccRCC samples. This work may facilitate the detection of ccRCC and serve as the basis for further studies of the clinical value of serum lncRNAs in maintaining surveillance and forecasting prognosis.

Identifiers

PMID26878386
PMCPMC5154346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.